Microba Life SciencesASX:MAP PB Ratio is 0.78 as of Jun. 26, 2026, which is 58% below its 10-year median of 1.85. The stock has 6 warning signs investors should review. Among 196 Medical Diagnostics & Research companies, Microba Life Sciences ranks better than 87.24% on this metric.
The historical rank and industry rank for Microba Life Sciences's PB Ratio or its related term are showing as below:
ASX:MAP'
s PB Ratio Range Over the Past 10 Years
Min: 0.59 Med: 1.85 Max: 3.47
Current: 0.78
During the past 4 years, Microba Life Sciences's highest PB Ratio was 3.47. The lowest was 0.59. And the median was 1.85.
ASX:MAP's PB Ratio is ranked better than 87.24% of 196
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.05
vs ASX:MAP: 0.78
During the past 12 months, Microba Life Sciences's average Book Value Per Share Growth Rate was -37.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -18.20% per year.
During the past 4 years, the highest 3-Year average Book Value Per Share Growth Rate of Microba Life Sciences was -18.20% per year. The lowest was -18.20% per year. And the median was -18.20% per year.
Back to Basics: PB Ratio
Microba Life Sciences (ASX:MAP) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Microba Life Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microba Life Sciences PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Microba Life Sciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Microba Life Sciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Microba Life Sciences (ASX:MAP) has a PB Ratio of 0.78 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Microba Life Sciences and its competitors. This is 58% below median its historical median of 1.85. Over the past decade, Microba Life Sciences' PB Ratio has ranged from 0.59 to 3.47. According to the industry distribution chart, Microba Life Sciences ranks #25 out of 196 companies in the Medical Diagnostics & Research industry, placing it in the top 12.8%.
Is Microba Life Sciences' PB Ratio too high?
Microba Life Sciences' current PB Ratio of 0.78 is 58% below median its 10-year median of 1.85. Over the past 10 years, this metric has ranged from a low of 0.59 to a high of 3.47. The Medical Diagnostics & Research industry median PB Ratio is 2.05. Microba Life Sciences' value of 0.78 is 62% below this industry median. Based on the distribution chart, Microba Life Sciences ranks #25 out of 196 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Microba Life Sciences' PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Microba Life Sciences ranks #25 out of 196 companies for PB Ratio. This places Microba Life Sciences in the top 13% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.05. Microba Life Sciences' value of 0.78 is 62% below this benchmark. Historically, Microba Life Sciences' own PB Ratio has ranged from 0.59 to 3.47 over the past decade. While the company's 10-year median is 1.85 vs. the industry median of 2.05, Microba Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.05, based on 196 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Microba Life Sciences's current PB Ratio of 0.78 is 62% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Microba Life Sciences and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Microba Life Sciences's current PB Ratio is 0.78, which is 58% below median its own 10-year median of 1.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microba Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Microba Life Sciences (ASX:MAP) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.25, compared to a current price of A$0.04 — trading 84.4% below its estimated fair value. The current PB Ratio is 0.78, which is 58% below median its 10-year median of 1.85 and 62% below the Medical Diagnostics & Research industry median of 2.05. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Microba Life Sciences (ASX:MAP), the current PB Ratio is 0.78 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MAP has been successfully added to your 